Preferred Label : Sabizabulin;
NCIt definition : An orally bioavailable, small molecule tubulin inhibitor, with potential antineoplastic,
antiviral and anti-inflammatory activities. Upon oral administration, sabizabulin
binds to the colchicine-binding site of alpha- and beta-tubulin subunits of microtubules
and crosslinks the microtubules, thereby inhibiting microtubule polymerization in
tumor blood vessel endothelial cells and tumor cells. This blocks the formation of
the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result,
this agent disrupts the tumor vasculature, tumor blood flow, deprives tumor cells
of nutrients, and induces apoptosis. In addition, as microtubules plays an important
role in intracellular transport, the inhibition of its polymerization may disrupt
the transport of the androgen receptor (AR) into the cell nucleus, as well as virus
trafficking around the cell. This may decrease viral replication and assembly. Inhibition
of tubulin polymerization may also inhibit the release of pro-inflammatory cytokines
and disrupt inflammatory cell activities. Sabizabulin is not a substrate of P-glycoprotein
(Pgp), an efflux pump that when overexpressed, may confer resistance to taxane agents.;
UNII : 37L1JX37J5;
CAS number : 1332881-26-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1332881-26-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : VERU-111; VERU 111;
NCI Metathesaurus CUI : CL1659534;
Origin ID : C158517;
UMLS CUI : C5435437;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
